Senti Biosciences Holdings, Inc.
Engineered living cells with genetic control circuits for IBD therapy
- Sector
- Biotech
- Headquarters
- South San Francisco, CA
- Founded
- 2021
- Latest Form D
- $10M, Jun 2026
- Total capital
- $50.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $47.6M
- 2 Form D · last Jun 2026
- 5 months since last filing
- Federal contracts
- $2.6M
- 2 awards · Defense, Health and Human S
- Rank in Biotech#121 of 4373
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$10M
- Private capital raisedForm D · SEC · 1st filing$37.6M
- Federal contractHealth and Human S · Topic 414 : Synthetic Biology Gene Circuits For Cancer Therapy$2M
- Federal contractDefense · Igf::ot::igf - Biological Technologies Office Study - Programmable Therapeutic Cell Circuit Platforms$583K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
100months
from Senti Biosciences Holdings, Inc.’s first federal award to its first private round.
- First federal award · Sep 2016
- Defense · $583K
- First Form D · Dec 2024
- $37.6M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Brenda D. CooperstoneDirectorNamed in SEC Form D filings
- Bryan J. BaumDirectorNamed in SEC Form D filings
- Donald D. TangDirectorNamed in SEC Form D filings
- Edward MathersDirectorNamed in SEC Form D filings
- Feng J. HsiungDirectorNamed in SEC Form D filings
- Frances D. SchulzDirectorNamed in SEC Form D filings
Show all 10 people
- James J. CollinsDirectorNamed in SEC Form D filings
- Jay J. CrossExecutive OfficerNamed in SEC Form D filings
- Kanya J. RajangamExecutive OfficerNamed in SEC Form D filings
- Timothy LuExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- TECHNOVAX INCSimilar federal contract value in Biotech · $2.7M in contracts
- OMICSCRAFT LLCSimilar federal contract value in Biotech · $2.7M in contracts
- RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLCSimilar federal contract value in Biotech · $2.6M in contracts
- Senti Biosciences, Inc.Similar federal contract value in Biotech · $2.6M in contracts
- TECHULON, INC.Similar federal contract value in Biotech · $2.5M in contracts
- REACTION BIOLOGY CORPORATIONSimilar federal contract value in Biotech · $2.5M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .